| Document |
Document Title |
|
WO/2007/067612A1 |
Compounds of the formula (I) are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as...
|
|
WO/2007/067614A1 |
Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inh...
|
|
WO/2007/057092A1 |
The invention relates to compounds of formula (I), in which R1, R2, m, Q and B are defined as cited in claim 1. Said compounds are inhibitors of tyrosine kinases, in particular of Met kinase and can be used, among other things, for treat...
|
|
WO/2007/057093A1 |
The invention relates to compounds of formula (I), in which R1, R2, Q and B are defined as cited in claim 1. Said compounds are inhibitors of tyrosine kinases, in particular of Met kinase, and can be used, among other things, for treatin...
|
|
WO/2007/054601A1 |
The invention relates to derivatives of 1,1-dioxo-1,2,6-thadiazine-5-carboxamide with chemical structure I and derivatives of 1,1-dioxo-1,2,6-thadiazine-5-alkyl carboxylate with chemical structure II, having cannabinoid properties, where...
|
|
WO/2007/054257A2 |
The present invention makes reference to new indene derivatives with general formula (I), as well as to their preparation procedures, their application as medicament and the pharmaceutical compositions containing them. The new compounds ...
|
|
WO/2007/056469A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2007/049828A1 |
Disclosed is a therapeutic agent for unstable cerebrospinal pressure syndrome. It is found that there exists a disease induced by a large fluctuation and instability in a cerebrospinal pressure compared to that in normal persons, and the...
|
|
WO/2007/041258A1 |
The present invention is directed to benzothiadiazolylphenylalkylamine derivatives of formula (I): or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and ...
|
|
WO/2007/039171A1 |
The invention relates to 4-oxy-N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARalpha, PPARdelta and PPARgamma agonist activity. What is ...
|
|
WO/2007/041366A1 |
The present invention provides compounds of the formula (I), which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds o...
|
|
WO/2007/039175A1 |
The invention relates to N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta and PPARgamma agonist activity. What is described are com...
|
|
WO/2007/039173A1 |
The invention relates to cyclic N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What ...
|
|
WO/2007/037187A1 |
A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represent...
|
|
WO/2007/031513A1 |
The present invention relates to aryloxy substituted phenylamidine derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide or insecticide active agents, particul...
|
|
WO/2007/026376A2 |
This invention relates to a process for the preparation and purification of a pure crystalline Hydrochlorothiazide with overall purity 99.9% or greater and single impurity below 0.1%. This is a two step process. In first step crude hydro...
|
|
WO/2007/022845A1 |
The invention relates to compounds of formula (1) and to the use thereof in organic electroluminescent devices. The compounds of formula (1) are used as host material or as a dopant in the emitting layer and/or as hole transport material...
|
|
WO/2007/017414A1 |
Dicyanoalkane compounds of formula (I), wherein R1, R2, R3,R4 and A are defined as in the description, or the enantiomers or diastereomers or salts thereof are subject matter of the present invention. Further also processes and intermedi...
|
|
WO/2007/017507A1 |
The invention relates to the substituted 1,2-ethylenediamines of general formula (I), wherein the groups R1 to R13, A, B, L and i are defined as in the description and the claims. The invention also relates to the use thereof in the trea...
|
|
WO/2007/017511A2 |
The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1 - R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating A...
|
|
WO/2007/012724A1 |
The invention relates to novel antifungal compounds of formula (I). Pharmaceutical antifungal compositions for using in human medicine and veterinary science containing the compound of formula (I), wherein x is a group selected from SO- ...
|
|
WO/2007/010653A1 |
A salt molten at room temperature that does not contain any organic solvent, excelling in stability; and a display device that is improved in the durability in high-temperature environment by virtue of the use thereof. There is provided ...
|
|
WO/2007/006814A1 |
The invention provides a compound of general formula (I) wherein the substituents are defined futher in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use...
|
|
WO/2007/007886A1 |
The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]: wherein Ring A is aryl or heteroaryl; Q is cycloalkyl, heterocycle, alkyl or alkeny...
|
|
WO/2007/005510A1 |
Certain /V-heteroarylpiperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions medi...
|
|
WO/2006/137490A1 |
A therapeutic and/or prophylactic agent for restenosis comprising a thiadiazoline derivative represented by the general formula (O) or a pharmaceutically acceptable salt thereof: wherein n represents an integer of 1 to 3; R0 represents a...
|
|
WO/2006/133588A1 |
It has been found that phenylurea compounds, in particular diphenylurea compounds of the formula (I), and pharmaceutically acceptable salts thereof are medicaments for the treatment of neurodegenerative diseases, in particular diseases i...
|
|
WO/2006/122319A2 |
Compounds, pharmaceutical compositions, kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of : formula (I) and formula (II) wherein the variables are as defined herein.
|
|
WO/2006/120133A2 |
The present invention concerns coloring keratin fibers, especially human hair, with colored metal complexes.
|
|
WO/2006/114260A1 |
The invention provides compounds of formula (I) wherein the substituents are as defined in the specification, to processes for their preparation and corresponding intermediates, and their use as modulators of the mglu5 receptor.
|
|
WO/2006/106960A1 |
A disulfonyl fluoride compound is easily and efficiently produced through a coupling reaction. The compound is converted to produce a useful compound. A compound (1) in which Y is fluorine is subjected to a photocoupling reaction, while ...
|
|
WO/2006/105127A2 |
Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: formula (I), wherein the variables are as defined herein.
|
|
WO/2006/102760A1 |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I); wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.
|
|
WO/2006/101102A1 |
Disclosed is an agent for treatment and/or prevention of solid tumors which contains a thiadiazoline derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof. [In the formula, n represents an...
|
|
WO/2006/101104A1 |
Disclosed is an agent for treatment and/or prevention of arthritis which contains a thiadiazoline derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof. [In the formula, n represents an in...
|
|
WO/2006/101103A1 |
Disclosed is an agent for treatment and/or prevention of hematopoietic tumor which contains a thiadiazoline derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof. [In the formula, n repres...
|
|
WO/2006/101105A1 |
Disclosed is an agent for treatment and/or prevention of psoriasis which contains a thiadiazoline derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof. [In the formula, n represents an in...
|
|
WO/2006/097449A1 |
New N-hydroxyamides of n-alkyl carboxylic acids omega substituted with suitable tricyclic systems characterised by a central 7-membered ring, having activity as inhibitors of histone deacetylase (HDAC).
|
|
WO/2006/098128A1 |
There are provided 1,2,3-thiadiazole compounds, or salts thereof, represented by the formula: (I) wherein each of R1, R2, R3, R4 and R5 is H, a halogen, CN, an alkyl, an alkoxyalkyl, an aryl, an arylalkyl, an alkylcarbonyl, etc.; and R6 ...
|
|
WO/2006/098308A1 |
An anthranilic acid derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a phenyl, cycloalkyl or bicyclic heterocyclic group which may...
|
|
WO/2006/093801A1 |
Compounds having the formula (I) are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employ...
|
|
WO/2006/084934A1 |
The invention relates to the use of heterocyclic compounds in the preparation of a medicament for regenerating damaged neuronal tissue. In a preferred embodiment of the invention, compounds having formula I are used to produce a medicame...
|
|
WO/2006/084854A2 |
The present invention relates to 5-imino-5H-[1,2,4]-dithiazol-3-yl-amine and [1,2,4]- dithiazolidine-3,5-diylidene-diamine derivatives as inducers of glutha-thione-S- transferase (GST) and NADPH quinone oxidoreductase (NQO), to methods f...
|
|
WO/2006/085108A1 |
Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2, W, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compo...
|
|
WO/2006/083271A2 |
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...
|
|
WO2006064375A9 |
The present invention relates to novel compounds selected from aminoaryl five-membered ring heterocycles that selectively modulate, regulate and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases imp...
|
|
WO/2006/072436A1 |
The present invention relates to compounds of the general formula (I) wherein R1 is-OR1’,-SR1’ or is a heterocycloalkyl group; R1’ is lower alkyl, lower alkyl substituted by halogen or is -(CH2)n-cycloalkyl; R2 is-S(O)2-lower alkyl...
|
|
WO/2006/069685A1 |
The invention relates to compounds of formula (I), where A1, A2, R1, R2, R3, R4, R5 and Y have the meanings given in the description, methods and intermediates for production thereof and use thereof for the prevention of pests.
|
|
WO/2006/068821A2 |
The present invention relates to intermediate compounds useful for the preparation of 1,2,5-thiadiazole compounds, including unsymmetrically substituted compounds such as 4-(3-secondary amino-2-hydroxy-propoxy)-1,2,5-thiadiazole compound...
|
|
WO/2006/064375A1 |
The present invention relates to novel compounds selected from aminoaryl five-membered ring heterocycles that selectively modulate, regulate and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases imp...
|
